The Patent Finder

TNF Pharmaceuticals, Inc.

19 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 11, 2026
    The maintenance fee for Methods of increasing hair growth and improving hair appearance (US 10,314,775) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
  • 1 fee due May 12, 2027
    The maintenance fee for Method of treating addictions to opioids (US 10,471,052) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
  • 1 fee due Jun 30, 2027
    The maintenance fee for Methods of altering programmed cell death and extending cell life (US 10,517,856) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 2 fees due Sep 17 to 26, 2027 · next Sep 17

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,884,055Method of treating substance addictions
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,471,052Method of treating addictions to opioids
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,517,856Methods of altering programmed cell death and extending cell life
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,588,899Methods of treating diabetes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,722,506Method of treating multiple sclerosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,786,493Method of treating viral infections
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,806,728Pharmaceutical salts of isomyosmine and pharmaceutical compositions containing same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,835,523Method of regulating tumor necrosis factor-alpha (TNF-α) for treating cancers, autoimmune disorders, and other disorders associated with chronic inflammation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,918,633Method of treating coronavirus
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,096,933Method of treating disorders associated with chronic inflammation
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited